- Home
- ROIV vs HSIC Comparison
ROIV vs HSIC Comparison
Compare ROIV & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- HSIC
- Stock Information
- Founded
- ROIV 2014
- HSIC 1932
- Country
- ROIV United Kingdom
- HSIC United States
- Employees
- ROIV N/A
- HSIC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- HSIC Medical Specialities
- Sector
- ROIV Health Care
- HSIC Health Care
- Exchange
- ROIV Nasdaq
- HSIC Nasdaq
- Market Cap
- ROIV 8.4B
- HSIC 8.1B
- IPO Year
- ROIV N/A
- HSIC 1995
- Fundamental
- Price
- ROIV $10.79
- HSIC $72.05
- Analyst Decision
- ROIV Buy
- HSIC Buy
- Analyst Count
- ROIV 4
- HSIC 10
- Target Price
- ROIV $17.50
- HSIC $79.30
- AVG Volume (30 Days)
- ROIV 5.9M
- HSIC 1.4M
- Earning Date
- ROIV 05-29-2025
- HSIC 05-05-2025
- Dividend Yield
- ROIV N/A
- HSIC N/A
- EPS Growth
- ROIV N/A
- HSIC 8.11
- EPS
- ROIV N/A
- HSIC 3.21
- Revenue
- ROIV $122,585,000.00
- HSIC $12,669,000,000.00
- Revenue This Year
- ROIV N/A
- HSIC $4.32
- Revenue Next Year
- ROIV N/A
- HSIC $3.51
- P/E Ratio
- ROIV N/A
- HSIC $22.29
- Revenue Growth
- ROIV 140.04
- HSIC 1.75
- 52 Week Low
- ROIV $8.73
- HSIC $60.56
- 52 Week High
- ROIV $13.06
- HSIC $82.49
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- HSIC 66.12
- Support Level
- ROIV $10.58
- HSIC $69.64
- Resistance Level
- ROIV $11.77
- HSIC $71.33
- Average True Range (ATR)
- ROIV 0.34
- HSIC 1.83
- MACD
- ROIV -0.07
- HSIC 0.81
- Stochastic Oscillator
- ROIV 17.65
- HSIC 99.37
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.